Elevated circulating sclerostin concentrations in individuals with High Bone Mass, with and without LRP5 mutations

Gregson, Celia L, Poole, Ken E S, McCloskey, Eugene V, Duncan, Emma L, Rittweger, Jörn, Fraser, William D, Smith, George Davey and Tobias, Jonathan H (2014) Elevated circulating sclerostin concentrations in individuals with High Bone Mass, with and without LRP5 mutations. The Journal of Clinical Endocrinology and Metabolism, 99 (8). 2897–2907. ISSN 0021-972X

Full text not available from this repository. (Request a copy)

Abstract

Context: The role and importance of circulating sclerostin is poorly understood. High Bone Mass (HBM) caused by activating LRP5 mutations has been reported to be associated with increased plasma sclerostin concentrations; whether the same applies to HBM due to other causes is unknown. Objective: To determine circulating sclerostin concentrations in HBM. Design: Case-control study Participants: 406 HBM index cases were identified by screening DXA databases from 4 UK centers (n=219,088), excluding significant osteoarthritis/artefact. Controls comprised unaffected relatives & spouses. Main measure(s): Plasma sclerostin, lumbar spine L1, total hip and total body DXA, and radial and tibial pQCT (subgroup only). Results: Sclerostin concentrations were significantly higher in both LRP5 HBM and non-LRP5 HBM cases, compared with controls; mean[SD] 130.1[61.7] and 88.0[39.3], vs. 66.4[32.3]pmol/L, both p

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Faculty of Science > School of Computing Sciences
Depositing User: Pure Connector
Date Deposited: 07 Jul 2014 13:08
Last Modified: 21 Apr 2020 23:05
URI: https://ueaeprints.uea.ac.uk/id/eprint/48839
DOI: 10.1210/jc.2013-3958

Actions (login required)

View Item View Item